Whole Genome & Exome Sequencing Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Whole genome sequencing is growing fast but has not yet taken off. This report estimates the global whole genome and exome sequencing market at $3,140 million in 2026, growing 19.3% a year to $7,600 million in 2031 and adding $4,460 million of new annual spending. Long-read sequencing grows from 13.5% to 22.5% of the market, hospitals and clinical laboratories overtake research institutes as the largest customers (25.5% to 34.5%), and rapid and critical care genome sequencing is the fastest-growing application at 39.0% a year. Yet routine genome sequencing of healthy people is at least five years away: the price of sequencing is no longer the barrier, but payment, interpretation, evidence of benefit and health records are, and the industry still needs a killer app. The report explains why and lists the signposts to watch.

The past year brought Illumina's $395 TruPath genome, Element's VITARI with a claimed $100 genome, Roche's AXELIOS launch, Ultima's UG200 series, PacBio's SPRQ-Nx chemistry, the BIOSECURE Act and the 1260H listing of BGI, MGI and Complete Genomics, China lifting its export ban on Illumina, a guidance cut at GeneDx, more than 535,000 whole genomes released by All of Us, and genomic newborn screening pilots entering US public health. The report covers 23 chapters, 61 tables and 53 figures, with forecasts by application, technology, sequencing scope, customer and product for 14 countries and regions, and profiles of 53 companies.

Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information.

Product Code: GENWHOLE 1026

List of Tables

List of Figures

1. Executive Summary

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis
1.5 When Will Whole Genome Sequencing Take Off?

2. Research Methodology & Scope

2.1 Scope & Market Definition
2.2 Value Basis
2.3 Market Segments
2.4 Geographic Coverage
2.5 Methodology
2.6 Sources
2.7 Author
2.8 Limitations

3. Introduction to Whole Genome & Exome Sequencing

3.1 The Genome and the Exome
3.2 Coverage, Depth and Read Length
3.3 From Sample to Variant Call
3.4 From the Human Genome Project to the $100 Genome
3.5 Sizing the Genome and Pricing Practice
3.6 The Industry and Its Players

4. The Global Market for Whole Genome & Exome Sequencing

4.1 Global Market Overview by Country
4.2 Global Market by Application - Overview
4.3 Global Market by Technology - Overview
4.4 Global Market by Sequencing Scope - Overview
4.5 Global Market by Customer - Overview
4.6 Global Market by Product - Overview

5. Clinical WGS & WES: Rare Disease, Rapid Critical Care and Newborn Genomics

5.1 The Diagnostic Odyssey and Why Genomes Help
5.2 Diagnostic Yield and First-Tier Testing
5.3 Rapid and Ultra-Rapid WGS in Critical Care
5.4 Genomic Newborn Screening
5.5 Reproductive and Carrier Genomics
5.6 Reanalysis, Interpretation and the Economics of a Clinical Genome

6. Population Genomics Programmes & Research Cohorts

6.1 Why Nations Sequence Their Populations
6.2 National Programmes in North America and Europe
6.3 Middle East and Asia-Pacific Programmes
6.4 Biopharma Sequencing Consortia and Health-System Cohorts
6.5 Technology Choices: Arrays, Exomes, Genomes and Long Reads
6.6 Outlook for Population Genomics

7. Technology Landscape

7.1 A Crowded Field After a Long Monopoly
7.2 Short-read Sequencing by Synthesis
7.3 DNA Nanoball and the New Low-cost Platforms
7.4 Long-read Sequencing
7.5 Accuracy, Read Length and the Cost per Genome
7.6 Technology Outlook

8. Instruments, Reagents, Services & Bioinformatics

8.1 How the Market Divides by Product
8.2 Instruments and the Installed Base
8.3 Reagents, Consumables and Pricing
8.4 Sequencing Service Providers and Clinical Laboratories
8.5 Bioinformatics, Interpretation and AI

9. Regulatory, Reimbursement & Policy

9.1 Policy as a Market Driver
9.2 Reimbursement in the United States
9.3 Test Regulation in the US and Europe
9.4 Data Privacy and Genomic Data Security
9.5 Geopolitics: BIOSECURE, China and Research Funding

10. Oncology, Infectious Disease, Consumer & Agricultural Applications

10.1 Four Applications Beyond the Germline Clinic
10.2 Oncology: Tumour-Normal Genomes and Whole-Genome MRD
10.3 Infectious Disease, Outbreaks and Wastewater
10.4 Consumer and Wellness Genomes
10.5 Agriculture, Livestock and Other Applications
10.6 Outlook for These Applications

11. China & Asia-Pacific Sequencing Ecosystem

11.1 Regional Overview
11.2 China: BGI, MGI, Novogene and Domestic Substitution
11.3 Illumina's Position in China
11.4 Japan, Korea, India, Singapore and Australia
11.5 Outlook for Asia-Pacific

12. Recent Developments

12.1 Illumina Launches TruPath Genome at AGBT
12.2 Element Biosciences Announces the VITARI Production-Scale Sequencer
12.3 Roche Commercially Launches AXELIOS 1 Sequencing by Expansion
12.4 BIOSECURE Becomes Law, BGI Units Listed, and MGI Agrees to Sell Complete Genomics
12.5 China Lifts Its Export Ban on Illumina
12.6 GeneDx Cuts 2026 Guidance After First-Quarter Miss
12.7 Ultima Genomics Launches the UG200 Series and Solaris 2.0
12.8 PacBio Ships SPRQ-Nx Chemistry
12.9 All of Us Releases More Than 535,000 Whole Genomes
12.10 Genomic Newborn Screening Enters US Public Health

13. Operations, Data & Supply Chain

13.1 The Sequencing Workflow and Turnaround
13.2 Automation and Laboratory Operations
13.3 Compute, Storage and Cloud
13.4 Data Sharing, Interpretation and AI
13.5 Reagent Supply Chain and Staffing
13.6 Operational Outlook

14. Competitive Landscape

14.1 Structure of Competition
14.2 Tiers of Players
14.3 Leading Players by Role
14.4 Competitive Dynamics
14.5 Outlook for Competition

15. SWOT, Porter's Five Forces & Investment Risk Analysis

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Investment Risk Analysis

16. Strategic Recommendations

16.1 Guidance for Executives, Marketing, Sales and Business Development
16.2 Guidance for Management Consultants and Investment Advisors

17. Market Forecast by Application, 2026-2031

17.1 Research & Population Genomics
17.2 Rare & Inherited Disease
17.3 Rapid & Critical Care WGS
17.4 Newborn & Reproductive Genomics
17.5 Oncology
17.6 Infectious Disease & Public Health
17.7 Consumer & Wellness
17.8 Agriculture, Animal & Other

18. Market Forecast by Technology, 2026-2031

18.1 Short-read Sequencing by Synthesis
18.2 DNA Nanoball
18.3 Long-read
18.4 Emerging Low-cost Platforms

19. Market Forecast by Sequencing Scope, 2026-2031

19.1 Whole Genome
19.2 Low-pass Genome
19.3 Whole Exome
19.4 Combined & Other

20. Market Forecast by Customer, 2026-2031

20.1 Academic & Research Institutes
20.2 Hospitals & Clinical Laboratories
20.3 Biopharma & CROs
20.4 Government & Public Health
20.5 Consumer & Other

21. Market Forecast by Product, 2026-2031

21.1 Instruments
21.2 Reagents & Consumables
21.3 Sequencing & Analysis Services
21.4 Software, Bioinformatics & Other

22. Company Profiles

22.1 Admera Health
22.2 Agilent Technologies
22.3 Ambry Genetics (Tempus)
22.4 Azenta Life Sciences (GENEWIZ)
22.5 Baylor Genetics
22.6 BGI Genomics
22.7 Broad Clinical Labs
22.8 Centogene
22.9 Complete Genomics
22.10 Dante Genomics (Dante Labs)
22.11 DNAnexus
22.12 Element Biosciences
22.13 Fulgent Genetics
22.14 Gencove
22.15 GeneDx
22.16 Genoox (Franklin, QIAGEN)
22.17 Hamilton Company
22.18 Helix
22.19 Illumina
22.20 Integrated DNA Technologies (Danaher)
22.21 Labcorp (including Invitae assets)
22.22 Macrogen
22.23 MGI Tech
22.24 Myriad Genetics
22.25 Natera
22.26 Nebula Genomics (DNA Complete)
22.27 New England Biolabs
22.28 Novogene
22.29 Nucleus Genomics
22.30 NVIDIA (Parabricks / Clara)
22.31 Oxford Nanopore Technologies
22.32 Pacific Biosciences
22.33 Personalis (Tempus AI)
22.34 Precure LLC (Mayo Clinic / Thermo Fisher)
22.35 Psomagen
22.36 Qiagen
22.37 Quest Diagnostics
22.38 Rady Children's Institute for Genomic Medicine (Rady Children's Health)
22.39 Regeneron Genetics Center (Regeneron)
22.40 Revvity
22.41 Revvity Omics (Revvity)
22.42 Roche (Sequencing Solutions / AXELIOS)
22.43 SeqOne (Congenica)
22.44 Sequencing.com
22.45 SOPHiA GENETICS
22.46 Tempus AI
22.47 Thermo Fisher Scientific
22.48 Truveta (Truveta Genome Project)
22.49 Twist Bioscience
22.50 Ultima Genomics
22.51 Variantyx
22.52 Velsera (Seven Bridges)
22.53 Watchmaker Genomics

23. Appendix

23.1 Abbreviations
23.2 Developments Archive
23.3 Report Limitations Restated

Product Code: GENWHOLE 1026

List of Tables

Table 1 Key Market Indicators (constant 2026 US$)
Table 2 Global Market by Segment, 2026 and 2031 (US$ millions, constant 2026 dollars)
Table 3 Signposts That Whole Genome Sequencing Is Taking Off
Table 4 Whole Genome, Whole Exome and Low-pass Sequencing Compared
Table 5 Milestones in the Cost of Sequencing a Human Genome
Table 6 Global Market by Country
Table 7 Global Market by Application
Table 8 Global Market by Technology
Table 9 Global Market by Sequencing Scope
Table 10 Global Market by Customer
Table 11 Global Market by Product
Table 12 Clinical Germline Applications, Market Size and Growth
Table 13 Diagnostic Yield of Genomic Testing in Rare Disease, Typical Published Ranges
Table 14 Selected Genomic Newborn Screening Programmes
Table 15 Selected National Population Genomics Programmes
Table 16 Selected Biopharma and Health-System Sequencing Initiatives
Table 17 Production-Scale Whole Genome Sequencing Platforms, October 2026
Table 18 Whole Genome and Exome Sequencing Market by Technology, 2026 and 2031
Table 19 Whole Genome and Exome Sequencing Market by Product, 2026 and 2031
Table 20 Main Types of Sequencing Service Provider
Table 21 Key Policy and Reimbursement Factors, October 2026
Table 22 Oncology, Infectious Disease, Consumer and Agricultural Segments, 2026 and 2031
Table 23 Roles of Genome Sequencing in Agriculture, Animal and Other Applications
Table 24 Asia-Pacific Whole Genome and Exome Sequencing Market by Country, 2026 and 2031
Table 25 Selected Asia-Pacific National Genomics Programmes
Table 26 Typical Turnaround by Workflow Step for Clinical Genome Sequencing
Table 27 Competitive Structure by Application
Table 28 Tiers of Whole Genome and Exome Sequencing Competitors
Table 29 Leading Sequencer Makers for Whole Genome and Exome Sequencing
Table 30 Leading Clinical WGS and WES Laboratories
Table 31 Leading Informatics and Interpretation Providers
Table 32 SWOT Analysis - Strengths and Weaknesses
Table 33 SWOT Analysis - Opportunities and Threats
Table 34 Porter's Five Forces Ratings
Table 35 Investment Risk Matrix
Table 36 Selected Growth Opportunities
Table 37 Research & Population Genomics by Country
Table 38 Rare & Inherited Disease by Country
Table 39 Rapid & Critical Care WGS by Country
Table 40 Newborn & Reproductive Genomics by Country
Table 41 Oncology by Country
Table 42 Infectious Disease & Public Health by Country
Table 43 Consumer & Wellness by Country
Table 44 Agriculture, Animal & Other by Country
Table 45 Short-read Sequencing by Synthesis by Country
Table 46 DNA Nanoball by Country
Table 47 Long-read by Country
Table 48 Emerging Low-cost Platforms by Country
Table 49 Whole Genome by Country
Table 50 Low-pass Genome by Country
Table 51 Whole Exome by Country
Table 52 Combined & Other by Country
Table 53 Academic & Research Institutes by Country
Table 54 Hospitals & Clinical Laboratories by Country
Table 55 Biopharma & CROs by Country
Table 56 Government & Public Health by Country
Table 57 Consumer & Other by Country
Table 58 Instruments by Country
Table 59 Reagents & Consumables by Country
Table 60 Sequencing & Analysis Services by Country
Table 61 Software, Bioinformatics & Other by Country

List of Figures

Figure 1 Key Graphic - Long Reads Come of Age: Whole Genome & Exome Sequencing Market by Technology, 2026 vs 2031
Figure 2 Size of Genome for Various Species
Figure 3 Global Market Pareto Chart
Figure 4 Global Market by Application - Base vs. Final
Figure 5 Global Market by Application Base Year
Figure 6 Global Market by Application End Year
Figure 7 Application Share by Year
Figure 8 Application Segments Growth
Figure 9 Global Market by Technology - Base vs. Final
Figure 10 Global Market by Technology Base Year
Figure 11 Global Market by Technology End Year
Figure 12 Technology Share by Year
Figure 13 Technology Segments Growth
Figure 14 Global Market by Sequencing Scope - Base vs. Final
Figure 15 Global Market by Sequencing Scope Base Year
Figure 16 Global Market by Sequencing Scope End Year
Figure 17 Sequencing Scope Share by Year
Figure 18 Sequencing Scope Segments Growth
Figure 19 Global Market by Customer - Base vs. Final
Figure 20 Global Market by Customer Base Year
Figure 21 Global Market by Customer End Year
Figure 22 Customer Share by Year
Figure 23 Customer Segments Growth
Figure 24 Global Market by Product - Base vs. Final
Figure 25 Global Market by Product Base Year
Figure 26 Global Market by Product End Year
Figure 27 Product Share by Year
Figure 28 Product Segments Growth
Figure 29 Research & Population Genomics Growth
Figure 30 Rare & Inherited Disease Growth
Figure 31 Rapid & Critical Care WGS Growth
Figure 32 Newborn & Reproductive Genomics Growth
Figure 33 Oncology Growth
Figure 34 Infectious Disease & Public Health Growth
Figure 35 Consumer & Wellness Growth
Figure 36 Agriculture, Animal & Other Growth
Figure 37 Short-read Sequencing by Synthesis Growth
Figure 38 DNA Nanoball Growth
Figure 39 Long-read Growth
Figure 40 Emerging Low-cost Platforms Growth
Figure 41 Whole Genome Growth
Figure 42 Low-pass Genome Growth
Figure 43 Whole Exome Growth
Figure 44 Combined & Other Growth
Figure 45 Academic & Research Institutes Growth
Figure 46 Hospitals & Clinical Laboratories Growth
Figure 47 Biopharma & CROs Growth
Figure 48 Government & Public Health Growth
Figure 49 Consumer & Other Growth
Figure 50 Instruments Growth
Figure 51 Reagents & Consumables Growth
Figure 52 Sequencing & Analysis Services Growth
Figure 53 Software, Bioinformatics & Other Growth

Whole Genome & Exome Sequencing Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Description

Table of Contents

List of Tables

Report Overview:

Table of Contents

List of Tables

List of Figures

1. Executive Summary

2. Research Methodology & Scope

3. Introduction to Whole Genome & Exome Sequencing

4. The Global Market for Whole Genome & Exome Sequencing

5. Clinical WGS & WES: Rare Disease, Rapid Critical Care and Newborn Genomics

6. Population Genomics Programmes & Research Cohorts

7. Technology Landscape

8. Instruments, Reagents, Services & Bioinformatics

9. Regulatory, Reimbursement & Policy

10. Oncology, Infectious Disease, Consumer & Agricultural Applications

11. China & Asia-Pacific Sequencing Ecosystem

12. Recent Developments

13. Operations, Data & Supply Chain

14. Competitive Landscape

15. SWOT, Porter's Five Forces & Investment Risk Analysis

16. Strategic Recommendations

17. Market Forecast by Application, 2026-2031

18. Market Forecast by Technology, 2026-2031

19. Market Forecast by Sequencing Scope, 2026-2031

20. Market Forecast by Customer, 2026-2031

21. Market Forecast by Product, 2026-2031

22. Company Profiles

23. Appendix

List of Tables

List of Figures